Furthermore, the dual-targeting strategy utilizing anti-VCAM1 mAbs and anti-GPC3 mAbs enhances the specificity and sensitivity of therapy toward both CTCs and primary tumor cells, thereby improving overall therapeutic outcomes [41, 163] (Fig. 5C). This evidence concerns the gene GPC3 and neoplasm.